Revolution Medicines Director Disposes $3.64 Million in Stock; Exercises Options Amid Mixed Analyst Views
Mark A. Goldsmith, a director at Revolution Medicines (RVMD), sold common shares totaling $3,644,353 on March 2, 2026, and executed option activity across March 1-2. The company recently reported a wider fourth-quarter 2025 loss driven by higher R&D and SG&A spend, while several analysts revised coverage and price targets.